Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336098 · ClinicalTrials.gov registry record · Phase 1
Study of SRF617 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Coherus Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT04336098: Completed Phase 1 study, sponsored by Coherus Oncology.
NCT04336098 is a Phase 1 study that has completed, run by Coherus Oncology. The registered enrollment target is 85 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04336098, a Phase 1 study, has completed, sponsored by Coherus Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
Primary Outcome
Evaluation of dose-limiting toxicity (DLT).
Interventions
- DRUG Pembrolizumab
- DRUG Gemcitabine
- DRUG Albumin-Bound Paclitaxel
- DRUG SRF617
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2020-03-16 |
| Est. Completion | 2023-08-25 |
| Phase | Phase 1 |
What the finished NCT04336098 record still lists
NCT04336098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT04336098 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04336098 about?
NCT04336098 is a clinical study titled "Study of SRF617 in Patients With Advanced Solid Tumors". A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
What is the current status of trial NCT04336098?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2020-03-16. Estimated completion is 2023-08-25.
What interventions are being tested in trial NCT04336098?
The interventions under investigation include: Pembrolizumab (DRUG), Gemcitabine (DRUG), Albumin-Bound Paclitaxel (DRUG), SRF617 (DRUG).
Who is sponsoring clinical trial NCT04336098?
This trial is sponsored by Coherus Oncology, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04336098's enrollment target sits among peer trials
85 656th of 2000 higher than 1,342 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI